L13P (p.Leu13Pro) variant of B2M (Beta-2-microglobulin)

L13P (p.Leu13Pro) in B2M (Beta-2-microglobulin) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.28 / 1. The record also includes population frequency data and structural context.

L13P (p.Leu13Pro) variant details